Shi Juan, Zheng Dexian
National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China.
Curr Opin Mol Ther. 2009 Oct;11(5):547-53.
Gene therapy has made significant progress in the past decade, and has strong promise for the treatment of chronic diseases. China has emerged as a pioneer in some fields of gene therapy and, in 2003, became the first country to commercialize a gene therapy product, Gendicine. H-101 (Ocorine), the second gene therapy-based medicine, was approved in China in 2005. Commercialization of these two gene therapy products provides China with worldwide recognition in the field of gene therapy. The progress of gene therapy in China has resulted in the establishment of several companies pursuing gene therapy technology for commercial purposes. This review summarizes the recent advances in gene therapy in China, including preclinical studies, clinical trials and product commercialization.
在过去十年中，基因治疗取得了重大进展，对慢性病的治疗具有巨大潜力。中国已成为基因治疗某些领域的先驱，并于2003年成为首个将基因治疗产品“今又生”商业化的国家。第二种基于基因治疗的药物“安柯瑞”于2005年在中国获批。这两种基因治疗产品的商业化使中国在基因治疗领域获得了全球认可。中国基因治疗的进展促使几家公司为商业目的而追求基因治疗技术。本综述总结了中国基因治疗的最新进展，包括临床前研究、临床试验和产品商业化。
